

# Giuseppe Derosa

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8891648/giuseppe-derosa-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

335  
papers

8,413  
citations

48  
h-index

71  
g-index

378  
ext. papers

9,527  
ext. citations

4.3  
avg, IF

6.26  
L-index

#	Paper	IF	Citations
335	Evaluation of the Effect on Sexual Performance of a Nutraceutical Combination Containing Alpha Lipoic Acid, L. and , Compared to Placebo, Avanafil or a Combination of Nutraceutical Plus Avanafil in Males With Type 2 Diabetes Mellitus With Erectile Dysfunction.. <i>Frontiers in Endocrinology</i> , <b>2022</b> , 13, 847240	5.7	0
334	PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, bvaa180	0.4	2
333	Quercetin Phytosome□ as a potential candidate for managing COVID-19. <i>Minerva Gastroenterology</i> , <b>2021</b> , 67, 190-195	3	11
332	Efficacy and Safety of Ertugliflozin in Patients with Type□2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV. <i>Diabetes Therapy</i> , <b>2021</b> , 12, 1279-1297	3.6	4
331	Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 605691	4.9	5
330	Quercetin Phytosome□ as a potential candidate for managing COVID-19. <i>Minerva Gastroenterology</i> , <b>2021</b> , 67,	3	5
329	Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease Treated With Metformin and Sulfonylurea. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, A331-A331	0.4	
328	Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 582556	8.4	2
327	Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 2359-2366	2.3	38
326	Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 2807-2816	2.3	44
325	Metabolic Actions of a Supplement of Ilex Paraguariensis (An Extract of the Leaf Standardized to 2% I-Deoxinojirimcina), White Mulberry and Chromium Picolinate in Nondiabetic Subjects with Dysglycemia: A Randomized Trial. <i>Life</i> , <b>2021</b> , 11,	3	1
324	Effects of experimental colitis in rats on incretin levels, inflammatory markers, and enteric neuronal function. <i>Archives of Medical Science</i> , <b>2021</b> , 17, 1087-1092	2.9	0
323	A role for quercetin in coronavirus disease 2019 (COVID-19). <i>Phytotherapy Research</i> , <b>2021</b> , 35, 1230-1236.7	6.7	78
322	Effects of Oral Administration of Alprazolam and Lorazepam as Hypnotics on Cardiovascular Parameters in Hypertensive Patients. <i>Journal of Clinical Psychopharmacology</i> , <b>2021</b> , 41, 191-195	1.7	0
321	Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention. <i>Drug Design, Development and Therapy</i> , <b>2020</b> , 14, 5367-5374	4.4	4
320	An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2020</b> , 13, 653-661	3.4	9
319	Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: Data from the Brisighella Heart Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2020</b> , 30, 907-914	4.4	17

318	Lipid-lowering nutraceuticals update on scientific evidence. <i>Journal of Cardiovascular Medicine</i> , <b>2020</b> , 21, 845-859	1.9	7
317	Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial. <i>International Journal for Vitamin and Nutrition Research</i> , <b>2020</b> , 1-10	1.7	2
316	Change of some oxidative stress parameters after supplementation with whey protein isolate in patients with type 2 diabetes. <i>Nutrition</i> , <b>2020</b> , 73, 110700	4.8	12
315	Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markers in the progression of diabetes in obese patients (The RESISTIN trial). <i>Cytokine</i> , <b>2020</b> , 127, 154947	4	22
314	Glyco-metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study). <i>Diabetes/Metabolism Research and Reviews</i> , <b>2020</b> , 36, e3219	7.5	3
313	Ilex paraguariensis, white mulberry and chromium picolinate in patients with pre-diabetes. <i>Phytotherapy Research</i> , <b>2020</b> , 34, 1377-1384	6.7	2
312	Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy. <i>Journal of Clinical Pharmacology</i> , <b>2019</b> , 59, 1391-1399	2.9	5
311	Ascophyllum nodosum and Fucus vesiculosus on glycemic status and on endothelial damage markers in dysglycemic patients. <i>Phytotherapy Research</i> , <b>2019</b> , 33, 791-797	6.7	9
310	Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study. <i>Drug Design, Development and Therapy</i> , <b>2019</b> , 13, 3647-3655	4.4	9
309	Ascophyllum Nodosum, Fucus Vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2019</b> , 12, 1861-1865	3.4	5
308	Effects of a nutraceutical combination of monacolin, l-bryzanol and l-aminobutyric acid on lipid profile and C-reactive protein in mice. <i>Archives of Medical Science</i> , <b>2019</b> , 15, 792-796	2.9	1
307	Nutraceutical Herbs and Insulin Resistance <b>2019</b> , 223-242		
306	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effectiveness of a Food Supplement Containing Creatine and D-Ribose Combined with a Physical Exercise Program in Increasing Stress Tolerance in Patients with Ischemic Heart Disease. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	2
305	Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne effects on cardiovascular mortality in patients with congestive heart failure: The COFFEE-IT study. <i>Pharmacological Research</i> , <b>2019</b> , 141, 46-52	10.2	2
304	Effect of pistachio on brachial artery diameter and flow-mediated dilatation: A systematic review and meta-analysis of randomized, controlled-feeding clinical studies. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2019</b> , 59, 328-335	11.5	9
303	Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial. <i>Phytomedicine</i> , <b>2018</b> , 42, 75-82	6.5	12
302	The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. <i>Journal of Cellular Physiology</i> , <b>2018</b> , 233, 153-161	7	96
301	Evaluation of BAG3 levels in healthy subjects, hypertensive patients, and hypertensive diabetic patients. <i>Journal of Cellular Physiology</i> , <b>2018</b> , 233, 1791-1795	7	3

300	Curcumin: A Natural Pan-HDAC Inhibitor in Cancer. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 123-129	3.3	34
299	Response to an oral fat load and effects on lipid profile, glycemia and high-sensitivity C-reactive protein after soybean extract consumption. <i>Archives of Medical Science</i> , <b>2018</b> , 14, 760-765	2.9	1
298	Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes. <i>Therapeutics and Clinical Risk Management</i> , <b>2018</b> , 14, 1637-1640	2.9	7
297	Retraction notice to "Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammatin" [European Journal of Pharmaceutical Sciences 51C (2013) 26-33]. <i>European Journal of Pharmaceutical Sciences</i> , <b>2018</b> , 122, 504	5.1	
296	A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients. <i>Drug Design, Development and Therapy</i> , <b>2018</b> , 12, 2611-2616	4.4	4
295	Effects of two different dialytic treatments on inflammatory markers in people with end-stage renal disease with and without type 2 diabetes mellitus. <i>Cytokine</i> , <b>2017</b> , 92, 75-79	4	6
294	Exosomes: Nanoparticulate tools for RNA interference and drug delivery. <i>Journal of Cellular Physiology</i> , <b>2017</b> , 232, 1660-1668	7	62
293	Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 721-728	6.7	95
292	Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 1380-1396	3.8	11
291	Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	47
290	Retraction notice to "Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study". <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 1248	3.2	
289	Retraction notice to "Evaluation of the positive effects on insulin-resistance and Ecell measurements of vildagliptin in addition to metformin in type 2 diabetic patients" [Pharmacol. Res. 73 (2013) 20-26]. <i>Pharmacological Research</i> , <b>2017</b> , 121, 255	10.2	1
288	Naturally occurring anti-cancer agents targeting EZH2. <i>Cancer Letters</i> , <b>2017</b> , 400, 325-335	9.9	44
287	Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q on lipid levels: a randomized, double-blind, placebo controlled study. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 1585-1592	4.4	17
286	High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 3425-3434	4.4	8
285	Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 2293-2300	4.4	4
284	Curcuminoids Lower Plasma Leptin Concentrations: A Meta-analysis. <i>Phytotherapy Research</i> , <b>2017</b> , 31, 1836-1841	6.7	15
283	Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial. <i>Cardiovascular Therapeutics</i> , <b>2017</b> , 35, 47-54	3.3	5

282	Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 1481-1488	4.4	23
281	Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	12
280	Evaluation of the Effects of Mesoglycan on Some Markers of Endothelial Damage and Walking Distance in Diabetic Patients with Peripheral Arterial Disease. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	4
279	Effect of Sibutramine on Plasma C-Reactive Protein, Leptin and Adipon ectin Concentrations: A Systematic Review and Meta-Analysis of Randomized Contr olled Trials. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 870-878	3.3	7
278	Traditional Markers in Liver Disease. <i>Biomarkers in Disease</i> , <b>2017</b> , 3-22		1
277	Histological Biomarkers of Nonalcoholic Fatty Liver Disease. <i>Biomarkers in Disease</i> , <b>2017</b> , 693-705		1
276	Overview of Biochemical Markers of Bone Metabolism. <i>Biomarkers in Disease</i> , <b>2017</b> , 3-21		1
275	Vascular Cell Adhesion Molecule-1 (VCAM-1) Expression in Liver Disease. <i>Biomarkers in Disease</i> , <b>2017</b> , 707-717		
274	The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus. <i>Clinical Nutrition</i> , <b>2016</b> , 35, 1091-5	5.9	19
273	Auraptene and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 929, 399-407	3.6	14
272	Olmesartan Combined With Amlodipine on Oxidative Stress Parameters in Type 2 Diabetics, Compared With Single Therapies: A Randomized, Controlled, Clinical Trial. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3084	1.8	6
271	Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. <i>BMC Cardiovascular Disorders</i> , <b>2016</b> , 16, 66	2.3	13
270	Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. <i>Drugs</i> , <b>2016</b> , 76, 947-56	12.1	38
269	Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases. <i>Molecular Diagnosis and Therapy</i> , <b>2016</b> , 20, 335-45	4.5	141
268	Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1095-6	59.2	42
267	Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , <b>2016</b> , 212, 160-8	3.2	39
266	Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 344-53	13.6	37
265	Retargeting the management of hypercholesterolemia - focus on evolocumab. <i>Therapeutics and Clinical Risk Management</i> , <b>2016</b> , 12, 1365-76	2.9	7

264	A Clinical Trial about a Food Supplement Containing Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	39
263	A review about biomarkers for the investigation of vascular function and impairment in diabetes mellitus. <i>Vascular Health and Risk Management</i> , <b>2016</b> , 12, 415-419	4.4	17
262	Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , <b>2016</b> , 111, 394-404	10.2	102
261	A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa (black seed) on blood pressure. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 2127-35	1.9	26
260	Improvement of plasma adiponectin, leptin and C-reactive protein concentrations by orlistat: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 819-34	3.8	20
259	Testing Pharmacological Profiles with Biomarkers Relevant to Cardiovascular Profiles <b>2016</b> , 3-26		
258	Ellagic Acid and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 928, 473-479	3.6	47
257	Piperine and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 928, 173-184	3.8	37
256	Vascular Cell Adhesion Molecule-1 (VCAM-1) Expression in Liver Disease. <i>Exposure and Health</i> , <b>2016</b> , 1-18.8	18.8	0
255	Histological Biomarkers of Nonalcoholic Fatty Liver Disease. <i>Exposure and Health</i> , <b>2016</b> , 1-13	8.8	
254	Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 807-18	3.8	27
253	Effects of n-3 pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. <i>BioFactors</i> , <b>2016</b> , 42, 316-22	6.1	32
252	Relationship between serum uric acid and electrocardiographic alterations in a large sample of general population: data from the Brisighella Heart Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2015</b> , 22, 129-34	2.9	12
251	Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 554-559	6.7	6
250	Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy. <i>Pharmacological Research</i> , <b>2015</b> , 100, 127-34	10.2	13
249	Nutraceuticals for the treatment of metabolic diseases: evidence from clinical practice. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2015</b> , 10, 297-304	4.1	7
248	Subjective effects of a combined lipid-lowering nutraceutical or ezetimibe on well-being and sexual performance in patients with perceived worsening of erectile function during statin treatment: a randomised clinical trial. <i>Nutrafoods</i> , <b>2015</b> , 14, 127-131		1
247	Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Pharmacological Research</i> , <b>2015</b> , 102, 63-70	10.2	54



246	Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study. <i>Journal of Medicinal Food</i> , <b>2015</b> , 18, 1270-3	2.8	13
245	Inhaled insulin: weighing the pros and cons. <i>Lancet Diabetes and Endocrinology</i> , <b>2015</b> , 3, 834-5	18.1	1
244	Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients. <i>European Journal of Pharmacology</i> , <b>2015</b> , 766, 31-6	5.3	9
243	EXAMINE: targeting risk and treatment in diabetes. <i>Lancet, The</i> , <b>2015</b> , 386, 1443	4.0	2
242	Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus. <i>Journal of Clinical Pharmacology</i> , <b>2015</b> , 55, 409-14	2.9	4
241	Retraction notice to "Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies": <i>J Am Soc Hypertens</i> 7 (2013) 32-39. <i>Journal of the American Society of Hypertension</i> , <b>2015</b> , 9, 822		
240	Retraction notice to "Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study": <i>J Am Soc Hypertens</i> 8 (2014) 422-428. <i>Journal of the American Society of Hypertension</i> , <b>2015</b> , 9, 822		
239	Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. <i>Hypertension Research</i> , <b>2015</b> , 38, 690-4	4.7	12
238	Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. <i>Scientific Reports</i> , <b>2015</b> , 5, 12603	4.9	3
237	Bicarbonate dialysis compared to hemodiafiltration on glycemic excursions in patients with end-stage renal disease with and without type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , <b>2015</b> , 29, 1136-41	3.2	1
236	A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. <i>Cardiovascular Diabetology</i> , <b>2015</b> , 14, 95	8.7	7
235	Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial. <i>Pharmacotherapy</i> , <b>2015</b> , 35, 983-90	5.8	5
234	Sulfonylureas and their use in clinical practice. <i>Archives of Medical Science</i> , <b>2015</b> , 11, 840-8	2.9	220
233	6D.07. <i>Journal of Hypertension</i> , <b>2015</b> , 33, e84	1.9	
232	Is it time to implement a standardized oral glucose and fat load test to detect high risk patients? Probably not yet. <i>Atherosclerosis</i> , <b>2015</b> , 243, 346-7	3.1	
231	Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. <i>Atherosclerosis</i> , <b>2015</b> , 239, 87-92	3.1	24
230	Prevalence and associations of erectile dysfunction in a sample of Italian males with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , <b>2015</b> , 108, 329-35	7.4	23
229	Berberis aristata/Silybum marianum fixed combination (Berberol(®)) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. <i>Phytomedicine</i> , <b>2015</b> , 22, 231-7	6.5	18

228	The effects of canrenone on inflammatory markers in patients with metabolic syndrome. <i>Annals of Medicine</i> , <b>2015</b> , 47, 47-52	1.5	7
227	Testing Pharmacological Profiles with Biomarkers Relevant to Cardiovascular Profiles <b>2015</b> , 1-24		1
226	Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. <i>Inflammation</i> , <b>2014</b> , 37, 154-62	5.1	5
225	Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes. <i>Diabetic Medicine</i> , <b>2014</b> , 31, 1515-23	3.5	12
224	Pharmacotherapy for Obesity <b>2014</b> , 261-277		
223	Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. <i>European Journal of Pharmaceutical Sciences</i> , <b>2014</b> , 51, 26-33	5.1	7
222	Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2014</b> , 39, 277-85	2.2	9
221	Diabetes: safety and efficacy of albiglutide—results from two trials. <i>Nature Reviews Endocrinology</i> , <b>2014</b> , 10, 514-6	15.2	
220	Glibenclamide and cardio-metabolic risk: a systematic review. <i>International Journal of Diabetes in Developing Countries</i> , <b>2014</b> , 34, 61-68	0.8	1
219	Long-term predictors of impaired fasting glucose and type 2 diabetes in subjects with family history of type 2 diabetes: a 12-years follow-up of the Brisighella Heart Study historical cohort. <i>Diabetes Research and Clinical Practice</i> , <b>2014</b> , 104, 183-8	7.4	14
218	Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments. <i>Atherosclerosis</i> , <b>2014</b> , 235, 81-3	3.1	9
217	Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study. <i>Journal of the American Society of Hypertension</i> , <b>2014</b> , 8, 422-8		5
216	Dietary and nutraceutical approach to type 2 diabetes. <i>Archives of Medical Science</i> , <b>2014</b> , 10, 336-44	2.9	41
215	Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 453-9	4	11
214	Cardiovascular drugs and mortality in hypertensive patients with atrial fibrillation: evidence of efficacy for a global approach. <i>Hypertension Research</i> , <b>2014</b> , 37, 492-3	4.7	
213	Are there mild and serious metabolic syndromes? The need for a graded diagnosis. <i>Journal of Cardiovascular Medicine</i> , <b>2014</b> , 15, 759-60	1.9	4
212	Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , <b>2014</b> , 63, 957-67	12.7	23
211	Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. <i>Fundamental and Clinical Pharmacology</i> , <b>2014</b> , 28, 221-9	3.1	23



210	Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. <i>Current Topics in Medicinal Chemistry</i> , <b>2014</b> , 14, 200-6	3	38
209	A randomized, placebo-controlled study on the effects of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters. <i>Journal of Biological Regulators and Homeostatic Agents</i> , <b>2014</b> , 28, 317-24	0.7	11
208	Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 817-26	5.8	19
207	Adipocytokine levels in obese and non-obese subjects: an observational study. <i>Inflammation</i> , <b>2013</b> , 36, 914-20	5.1	71
206	Effects of canrenone in patients with metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 2161-9	4	12
205	Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 1875-84	4	11
204	Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 2463-73	4	3
203	Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 1495-506	5.4	37
202	Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. <i>Clinical and Experimental Hypertension</i> , <b>2013</b> , 35, 301-7	2.2	5
201	Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. <i>Journal of the American Society of Hypertension</i> , <b>2013</b> , 7, 32-9		7
200	Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. <i>Nutrition Research</i> , <b>2013</b> , 33, 622-8	4	49
199	Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2013</b> , 38, 48-55	2.2	4
198	Assessment and management of left ventricular hypertrophy in Type 2 diabetes patients with high blood pressure. <i>Expert Review of Cardiovascular Therapy</i> , <b>2013</b> , 11, 719-28	2.5	4
197	A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. <i>Diabetes Technology and Therapeutics</i> , <b>2013</b> , 15, 214-22	8.1	14
196	A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and $\beta$ cell function: the triple oral therapy. <i>Diabetic Medicine</i> , <b>2013</b> , 30, 846-54	3.5	10
195	Effects of berberine on lipid profile in subjects with low cardiovascular risk. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 475-82	5.4	64
194	Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2013</b> , 25, 1113-22	2.2	12
193	Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. <i>Expert Opinion on Drug Safety</i> , <b>2013</b> , 12, 621-9	4.1	4

192	Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 371-84	4	4
191	Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2013</b> , 91, 724-32	2.4	14
190	Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. <i>Internal Medicine</i> , <b>2013</b> , 52, 2179-87	1.1	23
189	A curious case of hypoglycaemia. <i>Archives of Medical Science</i> , <b>2013</b> , 9, 752-4	2.9	1
188	Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate. <i>Archives of Medical Science</i> , <b>2013</b> , 9, 238-42	2.9	6
187	Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. <i>Journal of Biological Regulators and Homeostatic Agents</i> , <b>2013</b> , 27, 717-28	0.7	14
186	Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2012</b> , 37, 187-95	2.2	35
185	Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 341-7	6.7	11
184	Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction. <i>Endocrine Journal</i> , <b>2012</b> , 59, 611-9	2.9	9
183	Vildagliptin added to metformin on $\beta$ cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. <i>Diabetes Technology and Therapeutics</i> , <b>2012</b> , 14, 475-84	8.1	41
182	A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and $\beta$ cell function. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 2433-42	4	18
181	Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. <i>Journal of Clinical Lipidology</i> , <b>2012</b> , 6, 553-64	4.9	43
180	Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2012</b> , 17, 34-43	2.6	21
179	Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. <i>Expert Opinion on Biological Therapy</i> , <b>2012</b> , 12, 1113-24	5.4	123
178	Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, $\beta$ cell function and insulin resistance in type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , <b>2012</b> , 98, 51-60	7.4	54
177	Exenatide plus metformin compared with metformin alone on $\beta$ cell function in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , <b>2012</b> , 29, 1515-23	3.5	48
176	Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 1091-9	4	9
175	$\alpha$ -Glucosidase inhibitors and their use in clinical practice. <i>Archives of Medical Science</i> , <b>2012</b> , 8, 899-906	2.9	194

174	Optimizing glycemic control: clinical utility of exenatide prolonged release injection. <i>Research and Reports in Endocrine Disorders</i> , <b>2012</b> , 41		
173	Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. <i>Clinical Cardiology</i> , <b>2012</b> , 35, 359-64	3.3	23
172	Anti-obesity drugs: a review about their effects and their safety. <i>Expert Opinion on Drug Safety</i> , <b>2012</b> , 11, 459-71	4.1	129
171	Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. <i>Diabetic Medicine</i> , <b>2012</b> , 29, 24-31	3.5	14
170	Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. <i>Clinical Therapeutics</i> , <b>2012</b> , 34, 1221-36	3.5	47
169	GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. <i>Current Clinical Pharmacology</i> , <b>2012</b> , 7, 214-28	2.5	39
168	Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study. <i>Current Medical Research and Opinion</i> , <b>2012</b> , 28, 1435-45	2.5	18
167	Dipeptidyl peptidase-4 inhibitors: 3 years of experience. <i>Diabetes Technology and Therapeutics</i> , <b>2012</b> , 14, 350-64	8.1	45
166	Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 629-36	4	8
165	Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 2581-91	4	21
164	Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 164-71	2.2	33
163	Peroxisome proliferator-activated receptor- $\alpha$ agonists on glycemic control, lipid profile and cardiovascular risk. <i>Current Molecular Pharmacology</i> , <b>2012</b> , 5, 272-81	3.7	51
162	Difference in incidence of cough induced by imidapril and ramipril: Role of prostaglandin synthesis inhibition. <i>Biomedicine and Aging Pathology</i> , <b>2011</b> , 1, 73-77		1
161	Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. <i>Hypertension Research</i> , <b>2011</b> , 34, 1321-6	4.7	21
160	Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. <i>Hypertension Research</i> , <b>2011</b> , 34, 509-15	4.7	13
159	Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , <b>2011</b> , 91, 265-70	7.4	19
158	Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2011</b> , 4, 263-71	3.4	21
157	LONG-TERM EFFECTS OF A BERBERINE BASED NUTRACEUTICAL ON BODY WEIGHT AND INSULIN-SENSITIVITY IN NON DIABETIC HYPERLIPIDAEMIC PATIENTS. <i>Journal of Hypertension</i> , <b>2011</b> , 29, e160	1.9	2

156	Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2011</b> , 36, 592-601	2.2	8
155	Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. <i>Fundamental and Clinical Pharmacology</i> , <b>2011</b> , 25, 642-51	3.1	22
154	Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. <i>Metabolism: Clinical and Experimental</i> , <b>2011</b> , 60, 421-9	12.7	28
153	Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. <i>European Journal of Pharmacology</i> , <b>2011</b> , 651, 240-50	5.3	41
152	Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. <i>European Journal of Pharmacology</i> , <b>2011</b> , 666, 251-6	5.3	57
151	Effects of n-3 PUFA on insulin resistance after an oral fat load. <i>European Journal of Lipid Science and Technology</i> , <b>2011</b> , 113, 950-960	3	16
150	Drug safety evaluation of amlodipine. <i>Expert Opinion on Drug Safety</i> , <b>2011</b> , 10, 795-804	4.1	17
149	Pioglitazone is a valid alternative to rosiglitazone. <i>American Journal of Cardiovascular Drugs</i> , <b>2011</b> , 11, 357-62	4	10
148	Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 2441-8	4	12
147	Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. <i>Hormone and Metabolic Research</i> , <b>2011</b> , 43, 505-12	3.1	27
146	Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 1351-8	4	12
145	Nateglinide does not reduce the incidence of diabetes or cardiovascular outcomes in people with impaired glucose tolerance and cardiovascular disease or risk factors. <i>Evidence-Based Medicine</i> , <b>2011</b> , 16, 7-8		2
144	Nifedipine and telmisartan for the treatment of hypertension: the TALENT study. <i>Expert Review of Cardiovascular Therapy</i> , <b>2011</b> , 9, 1499-503	2.5	2
143	Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. <i>Hypertension Research</i> , <b>2011</b> , 34, 145-51	4.7	31
142	Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2010</b> , 35, 565-79	2.2	29
141	Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination. <i>Integrated Blood Pressure Control</i> , <b>2010</b> , 3, 21-30	3.5	4
140	Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , <b>2010</b> , 13, 378-90	3.4	10
139	Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine. <i>Vascular Health and Risk Management</i> , <b>2010</b> , 6, 87-93	4.4	8

138	Candesartan effect on inflammation in hypertension. <i>Hypertension Research</i> , <b>2010</b> , 33, 209-13	4.7	18
137	Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 1971-82	4	25
136	Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. <i>Expert Review of Cardiovascular Therapy</i> , <b>2010</b> , 8, 835-43	2.5	12
135	Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome. <i>Clinical and Experimental Hypertension</i> , <b>2010</b> , 32, 245-50	2.2	7
134	Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. <i>Hormone and Metabolic Research</i> , <b>2010</b> , 42, 892-6	3.1	23
133	Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. <i>Hormone and Metabolic Research</i> , <b>2010</b> , 42, 663-9	3.1	45
132	Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients. <i>Hormone and Metabolic Research</i> , <b>2010</b> , 42, 8-13	3.1	36
131	Effect of body weight loss and normalization on blood pressure in overweight non-obese patients with stage 1 hypertension. <i>Hypertension Research</i> , <b>2010</b> , 33, 236-42	4.7	25
130	Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: a retrospective study. <i>Clinical and Experimental Hypertension</i> , <b>2010</b> , 32, 137-44	2.2	39
129	Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. <i>Hypertension Research</i> , <b>2010</b> , 33, 790-5	4.7	21
128	Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. <i>Drugs</i> , <b>2010</b> , 70, 1945-61	12.1	51
127	Effects of thiazolidinediones and sulfonylureas in patients with diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2010</b> , 12, 491-501	8.1	28
126	Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. <i>Microvascular Research</i> , <b>2010</b> , 79, 144-9	3.7	22
125	Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. <i>Microvascular Research</i> , <b>2010</b> , 80, 110-5	3.7	24
124	Exenatide versus glibenclamide in patients with diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2010</b> , 12, 233-40	8.1	97
123	Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. <i>Endocrine Journal</i> , <b>2010</b> , 57, 777-86	2.9	42
122	Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. <i>Internal Medicine</i> , <b>2010</b> , 49, 1717-25	1.1	29
121	Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. <i>Advances in Therapy</i> , <b>2010</b> , 27, 48-55	4.1	11



120	Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet. <i>Mediterranean Journal of Nutrition and Metabolism</i> , <b>2010</b> , 3, 47-54	1.3	52
119	Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , <b>2010</b> , 59, 887-95	12.7	93
118	Red yeast rice and statin-intolerant patients. <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 1504	3	14
117	Glimepiride-pioglitazone Hydrochloride in the Treatment of Type 2 Diabetes. <i>Clinical Medicine Therapeutics</i> , <b>2009</b> , 1, CMT.S2016		
116	Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 1973-83	2.5	33
115	Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study. <i>Diabetes Technology and Therapeutics</i> , <b>2009</b> , 11, 159-69	8.1	16
114	Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2009</b> , 16, 698-704		10
113	Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. <i>Hormone and Metabolic Research</i> , <b>2009</b> , 41, 893-8	3.1	30
112	Re: The influence of statin medications on prostate-specific antigen levels. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 610; author reply 610-1	9.7	
111	Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. <i>Heart and Vessels</i> , <b>2009</b> , 24, 204-10	2.1	37
110	Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2009</b> , 34, 13-23	2.2	14
109	Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2009</b> , 34, 267-76	2.2	17
108	Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2009</b> , 11, 1091-9	6.7	36
107	Efficacy and safety of two treatment combinations of hypertension in very elderly patients. <i>Archives of Gerontology and Geriatrics</i> , <b>2009</b> , 48, 401-5	4	26
106	Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. <i>Biomedicine and Pharmacotherapy</i> , <b>2009</b> , 63, 723-33	7.5	14
105	Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 600 study. <i>Metabolism: Clinical and Experimental</i> , <b>2009</b> , 58, 1059-66	12.7	18
104	Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 607-15	2.5	30
103	Effects of long chain omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 1239-47	4	22



102	Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives. <i>Blood Pressure</i> , <b>2009</b> , 18, 111-6	1.7	8
101	Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. <i>Internal Medicine</i> , <b>2009</b> , 48, 265-71	1.1	10
100	Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI). <i>Endocrine Journal</i> , <b>2009</b> , 56, 571-8	2.9	5
99	Irbesartan and hydrochlorothiazide association in the treatment of hypertension. <i>Current Vascular Pharmacology</i> , <b>2009</b> , 7, 120-36	3.3	2
98	Risk management in the treatment of type 2 diabetes with pioglitazone. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2009</b> , Volume 2, 51-60	3.4	
97	Risk management in the treatment of type 2 diabetes with pioglitazone. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2009</b> , 2, 51-60	3.4	1
96	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. <i>Clinical and Investigative Medicine</i> , <b>2009</b> , 32, E124-32	0.9	32
95	Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet. <i>Mediterranean Journal of Nutrition and Metabolism</i> , <b>2009</b> , 3, 47-54	1.3	
94	Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. <i>Archives of Medical Research</i> , <b>2008</b> , 39, 412-9	6.6	15
93	Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. <i>Metabolism: Clinical and Experimental</i> , <b>2008</b> , 57, 1552-7	12.7	14
92	Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. <i>American Journal of Hypertension</i> , <b>2008</b> , 21, 1034-9	2.3	62
91	Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. <i>Current Therapeutic Research</i> , <b>2008</b> , 69, 1-15	2.4	13
90	11.11 Effect of Valsartan-Amlodipine Combination on Cognitive Function In Elderly Hypertensive Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2008</b> , 15, 307-307	2.9	
89	Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. <i>Journal of Cardiovascular Pharmacology</i> , <b>2008</b> , 51, 217-22	3.1	36
88	Matrix metalloproteinase-2 and -9 levels in obese patients. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2008</b> , 15, 219-24		107
87	Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. <i>Hypertension Research</i> , <b>2008</b> , 31, 43-50	4.7	18
86	Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. <i>Internal Medicine</i> , <b>2008</b> , 47, 361-6	1.1	25
85	Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. <i>Internal Medicine</i> , <b>2008</b> , 47, 1851-7	1.1	15

84	Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. <i>Current Clinical Pharmacology</i> , <b>2008</b> , 3, 77-84	2.5	14
83	A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study. <i>Mediterranean Journal of Nutrition and Metabolism</i> , <b>2008</b> , 1, 33-36	1.3	2
82	A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study. <i>Mediterranean Journal of Nutrition and Metabolism</i> , <b>2008</b> , 1, 33-36	1.3	3
81	Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. <i>Core Evidence</i> , <b>2008</b> , 2, 189-98	4.9	3
80	Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2007</b> , 14, 45-51		29
79	Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. <i>Internal Medicine Journal</i> , <b>2007</b> , 37, 79-86	1.6	40
78	Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2007</b> , 32, 261-8	2.2	64
77	Pioglitazone plus glimepiride: a promising alternative in metabolic control. <i>International Journal of Clinical Practice</i> , <b>2007</b> , 61, 28-36	2.9	6
76	Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. <i>Heart and Vessels</i> , <b>2007</b> , 22, 361-70	2.1	55
75	Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. <i>Hypertension Research</i> , <b>2007</b> , 30, 387-94	4.7	52
74	Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2007</b> , 14, 175-83		11
73	Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , <b>2007</b> , 8, 139-44	3	11
72	Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. <i>Internal Medicine</i> , <b>2007</b> , 46, 1837-46	1.1	20
71	Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. <i>American Journal of Hypertension</i> , <b>2007</b> , 20, 417-22	2.3	37
70	Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. <i>Clinical Therapeutics</i> , <b>2007</b> , 29, 602-10	3.5	20
69	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. <i>Diabetes and Metabolism</i> , <b>2007</b> , 33, 129-34	5.4	100
68	Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. <i>Journal of Human Hypertension</i> , <b>2007</b> , 21, 220-4	2.6	86
67	Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2007</b> , 14, 193-8		33

66	Different effect of psyllium and guar dietary supplementation on blood pressure control in hypertensive overweight patients: a six-month, randomized clinical trial. <i>Clinical and Experimental Hypertension</i> , <b>2007</b> , 29, 383-94	2.2	59
65	Optimizing combination treatment in the management of type 2 diabetes. <i>Vascular Health and Risk Management</i> , <b>2007</b> , 3, 665-71	4.4	26
64	Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. <i>European Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 817-22	2.8	35
63	Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. <i>Advances in Therapy</i> , <b>2006</b> , 23, 680-95	4.1	15
62	Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. <i>Journal of International Medical Research</i> , <b>2006</b> , 34, 545-55	1.4	18
61	Glibenclamide plus metformin combination tablets are effective, convenient and well tolerated in the treatment of type 2 diabetes mellitus. <i>Drugs and Therapy Perspectives</i> , <b>2006</b> , 22, 1-6	1.5	1
60	Matrix Metalloproteinase-2, -9 and Tissue Inhibitor Metalloproteinase-1 in Patients with Hypertension Before and After Doxazosin Therapy. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2006</b> , 13, 47-52	2.9	2
59	Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2006</b> , 13, 227-31		107
58	Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. <i>Clinical Drug Investigation</i> , <b>2006</b> , 26, 529-39	3.2	9
57	Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. <i>Clinical Therapeutics</i> , <b>2006</b> , 28, 679-88	3.5	55
56	Recommendations for the treatment of hypertension in patients with DM: critical evaluation based on clinical trials. <i>Current Clinical Pharmacology</i> , <b>2006</b> , 1, 21-33	2.5	4
55	Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2006</b> , 3, 559-569		
54	Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>2006</b> , 47, 508-12	3.1	7
53	Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2006</b> , 8, 197-205	6.7	31
52	Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2006</b> , 31, 375-83	2.2	74
51	Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. <i>Hypertension Research</i> , <b>2006</b> , 29, 849-56	4.7	70
50	Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2006</b> , 3, 559-569		
49	Prospects for the development of novel anti-hyperlipidemic drugs. <i>Current Opinion in Investigational Drugs</i> , <b>2006</b> , 7, 826-33		6

48	Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. <i>Clinical Therapeutics</i> , <b>2005</b> , 27, 1383-91	3.5	36
47	A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. <i>Diabetes Research and Clinical Practice</i> , <b>2005</b> , 69, 5-13	7.4	70
46	Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , <b>2005</b> , 70, 119-25	7.4	29
45	Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. <i>Biomedicine and Pharmacotherapy</i> , <b>2005</b> , 59, 312-7	7.5	14
44	Effect of valsartan on adiponectine, leptin and resistin in hypertensive obese patients. <i>American Journal of Hypertension</i> , <b>2005</b> , 18, A196-A197	2.3	1
43	Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone. <i>Drugs and Aging</i> , <b>2005</b> , 22, 393-403	4.7	17
42	Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. <i>Hypertension Research</i> , <b>2005</b> , 28, 209-14	4.7	43
41	Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. <i>Hypertension Research</i> , <b>2005</b> , 28, 917-24	4.7	42
40	Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: a possible role for the coenzyme Q10?. <i>BioFactors</i> , <b>2005</b> , 23, 7-14	6.1	17
39	Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. <i>Diabetes, Obesity and Metabolism</i> , <b>2005</b> , 7, 47-55	6.7	55
38	Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. <i>Pharmacotherapy</i> , <b>2005</b> , 25, 637-45	5.8	16
37	Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. <i>Journal of International Medical Research</i> , <b>2005</b> , 33, 284-94	1.4	24
36	IFN-gamma low production capacity in type 1 diabetes mellitus patients at onset of disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2005</b> , 113, 313-7	2.3	12
35	Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardio-vascular disease: response to Beishuizen et al. <i>Diabetes Care</i> , <b>2005</b> , 28, 1262-3; author reply 1263-4	14.6	15
34	Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>2005</b> , 45, 599-604	3.1	26
33	Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. <i>Hypertension Research</i> , <b>2004</b> , 27, 457-64	4.7	140
32	Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes. <i>Diabetes Care</i> , <b>2004</b> , 27, 273-4	14.6	17
31	Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. <i>Journal of Human Hypertension</i> , <b>2004</b> , 18, 687-91	2.6	26

30	Association between low-molecular weight apolipoprotein(a) isoforms and obesity in Italian women. <i>Obesity</i> , <b>2004</b> , 12, 1322-6		1
29	What do herbalists suggest to diabetic patients in order to improve glycemic control? Evaluation of scientific evidence and potential risks. <i>Acta Diabetologica</i> , <b>2004</b> , 41, 91-8	3.9	46
28	Effect of oral chronic isoflavones supplementation on male rat sexual performances and sexual hormone plasma levels. <i>Phytotherapy Research</i> , <b>2004</b> , 18, 849-52	6.7	3
27	Effects of Siberian ginseng ( <i>Eleutherococcus senticosus maxim.</i> ) on elderly quality of life: a randomized clinical trial. <i>Archives of Gerontology and Geriatrics</i> , <b>2004</b> , 38, 69-73	4	22
26	Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. <i>Clinical Therapeutics</i> , <b>2004</b> , 26, 1599-607	3.5	70
25	Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. <i>American Journal of Hypertension</i> , <b>2004</b> , 17, 823-7	2.3	36
24	Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. <i>Clinical Therapeutics</i> , <b>2004</b> , 26, 1228-36	3.5	74
23	Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. <i>Clinical Therapeutics</i> , <b>2004</b> , 26, 744-54	3.5	127
22	EFFECT OF AMLODIPINE-ATORVASTATIN COMBINATION ON FIBRINOLYSIS IN HYPERTENSIVE HYPERCHOLESTEROLEMIC INSULIN-RESISTANT PATIENTS. <i>Journal of Hypertension</i> , <b>2004</b> , 22, S365	1.9	
21	Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. <i>Diabetes, Nutrition &amp; Metabolism</i> , <b>2004</b> , 17, 143-50		21
20	Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. <i>Diabetes, Nutrition &amp; Metabolism</i> , <b>2004</b> , 17, 222-9		29
19	Perindopril and candesartan comparative efficacy and safety in type II diabetic hypertensive patients. <i>Journal of Human Hypertension</i> , <b>2003</b> , 17, 433-5	2.6	4
18	Influence of losartan and atenolol on memory function in very elderly hypertensive patients. <i>Journal of Human Hypertension</i> , <b>2003</b> , 17, 781-5	2.6	101
17	Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. <i>Diabetes Research and Clinical Practice</i> , <b>2003</b> , 60, 161-9	7.4	47
16	Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 1107-22	3.5	60
15	Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 472-84	3.5	64
14	The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 1429-39	3.5	92
13	A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 2006-21	3.5	27



12	Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. <i>American Journal of Hypertension</i> , <b>2003</b> , 16, 596-9	2.3	27
11	Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. <i>European Journal of Clinical Pharmacology</i> , <b>2002</b> , 58, 177-80	2.8	105
10	Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: A double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. <i>Current Therapeutic Research</i> , <b>2002</b> , 63, 1-14	2.4	10
9	Effects of fosinopril on blood pressure, lipid profile, and lipoprotein(a) levels in normotensive patients with type 2 diabetes and microalbuminuria: An open-label, uncontrolled study. <i>Current Therapeutic Research</i> , <b>2002</b> , 63, 216-226	2.4	3
8	Effects of orlistat, simvastatin, and orlistat + simvastatin in obese patients with hypercholesterolemia: a randomized, open-label trial. <i>Current Therapeutic Research</i> , <b>2002</b> , 63, 621-633	2.4	15
7	Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. <i>American Journal of Hypertension</i> , <b>2002</b> , 15, 316-20	2.3	60
6	Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. <i>American Journal of Hypertension</i> , <b>2002</b> , 15, A35	2.3	
5	Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. <i>American Journal of Hypertension</i> , <b>2002</b> , 15, A36	2.3	
4	Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. <i>American Journal of Hypertension</i> , <b>2002</b> , 15, 1042-9	2.3	72
3	Smaller, denser LDL particles are not a risk factor for cardiovascular disease in healthy nonagenarian women of the Cremona Population Study. <i>Atherosclerosis</i> , <b>1998</b> , 140, 65-70	3.1	13
2	Effects of a restricted sleep regimen on ambulatory blood pressure monitoring in normotensive subjects. <i>American Journal of Hypertension</i> , <b>1996</b> , 9, 503-5	2.3	122
1	Metformin: From Immediate Release to Extended Release Formula, Effectiveness, And Safety in Patients With Chronic Kidney Disease. <i>European Medical Journal Diabetes</i> , 70-78	1	